Publication Type : Journal Article
Publisher : Frontiers in Chemistry
Source : Frontiers in Chemistry, Volume 8, p.624716 (2021)
Url : https://pubmed.ncbi.nlm.nih.gov/33732682/
Campus : Mysuru
School : School of Arts and Sciences
Department : Sciences
Year : 2021
Abstract : Annona muricata, a tropical plant which has been extensively used in ethnomedicine to treat a wide range of diseases, from malaria to cancer. Interestingly, this plant has been reported to demonstrate significant antiviral properties against the human immunodeficiency virus, herpes simplex virus, human papilloma virus, hepatitis C virus and dengue virus. Additionally, the bioactive compounds responsible for antiviral efficacy have also shown to be selectively cytotoxic while inhibiting tumorigenic cell growth without affecting the normal cell growth. Annonaceous Acetogenins are a class of bioactive compounds exclusive to the Annonaceae family at which the plant belongs. In the current study, we have created a library of Acetogenins unique to the plant, comprising of Annomuricin A, Annomuricin B, Annomuricin C, Muricatocin C, Muricatacin, -Annonacin, Annonacin-10-one, -Goniothalamicin, Arianacin and Javoricin, for and theoretical evaluations against the SARS-CoV-2 spike protein in an attempt toward promotion of plant based drug development for the current pandemic of coronavirus disease 2019 (COVID-19). We found that all the Acetogenins showing spike protein significantly docking with good binding affinities. Moreover, we envision Acetogenins can be further studied by and models to identify potential anti-SARS-CoV-2 agents.
Cite this Research Publication : S. K. Prasad, Pradeep, S., Shimavallu, C., Shiva Prasad Kollur, Syed, A., Marraiki, N., Egbuna, C., Gaman, M. - A., Kosakowska, O., Cho, W. C., Patrick-Iwuanyanwu, K. Chukwuemek, Castro, J. Ortega, Frau, J., Flores-Holguín, N., and Glossman-Mitnik, D., “Evaluation of Acetogenins as Potential Anti-SARS-CoV-2 Agents Through Computational Approaches.”, Frontiers in Chemistry, vol. 8, p. 624716, 2021.